Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testosterone therapy in erectile dysfunction and hypogonadism.

Ridwan Shabsigh1

  • 1Department of Urology, Columbia University, New York, NY 10032, USA. rs66@columbia.edu

The Journal of Sexual Medicine
|January 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual Field Testing on the Envision Head-Mounted Perimeter with and without Gaming Elements.

Ophthalmology. Glaucoma·2026
Same author

Testosterone and Covid-19: An update.

Reviews in medical virology·2022
Same author

Ethics of Artificial Intelligence in Medicine and Ophthalmology.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2021
Same author

Sex-based differences in severity and mortality in COVID-19.

Reviews in medical virology·2021
Same author

Letter: Dismantling the Apocalypse Narrative: The Myth of the COVID-19 Stroke.

Neurosurgery·2020
Same author

Integration of Geriatrician Consultation for Trauma Admissions May Benefit Patient Outcomes.

Gerontology & geriatric medicine·2019

Testosterone therapy combined with PDE5 inhibitors significantly improves erectile function in hypogonadal men who did not respond to PDE5 inhibitors alone. This combination therapy enhances orgasmic function and patient satisfaction, offering a new treatment option for erectile dysfunction (ED).

Area of Science:

  • Andrology
  • Urology
  • Endocrinology

Background:

  • The nitric oxide pathway is crucial for erectile function and is testosterone-dependent.
  • Castration leads to erectile dysfunction (ED) by reducing nitric oxide synthase and phosphodiesterase type 5 (PDE5), causing apoptosis and veno-occlusive dysfunction.
  • Testosterone therapy can reverse these changes and improve erectile function in hypogonadal men, but monotherapy may be insufficient for multifactorial ED.

Purpose of the Study:

  • To evaluate the efficacy of combining testosterone gel with a PDE5 inhibitor (sildenafil) in hypogonadal men with ED.
  • To determine if this combination therapy improves erectile response in men who previously failed sildenafil monotherapy.

Main Methods:

  • A review of preliminary data and a multicenter, randomized, placebo-controlled study.

Related Experiment Videos

  • Hypogonadal men with ED who failed prior sildenafil treatment were screened and randomized.
  • Participants received either testosterone gel 1% plus sildenafil or placebo gel plus sildenafil for 12 weeks.

    • Main Results:

    • Screening confirmed a prevalence of hypogonadism in ED patients unresponsive to sildenafil.
    • Testosterone gel combined with sildenafil significantly improved erectile function compared to placebo.
    • The combination therapy also led to significant improvements in orgasmic function and overall patient satisfaction.

    Conclusions:

    • All men with ED should be screened for hypogonadism, particularly those with inadequate response to PDE5 inhibitors.
    • Combining testosterone with PDE5 inhibitors is a viable treatment option for ED in men with low testosterone levels who have not responded adequately to PDE5 inhibitors alone.